Johannes Melms

Excited to share a new paper: tinyurl.com/49u5e6by @CellCellPress: a framework to accelerate variant classification, diagnosis & treatment of immune disorders & genetic disorders more broadly. Led by superstar, juggernaut & future dermatologist @zwalsh96

Mapping variant effects on anti-tumor hallmarks of primary human T cells with base-editing screens go.nature.com/3yxjW7q

Very excited to share new work from the lab dissecting mechanisms of liver-metastatic organotropism in melanoma and other cancers. Huge congrats to fearless post-doc @meri_rogava (on the job market!) who led this multi-year study! Below a brief summary... nature.com/articles/s4301…

Interested in T cell biology? Cellular immunotherapies? Base editing? And an amazing example for scientific reproducibility- this @biorxivpreprint & tweetorial are for you! TL:DR- we made primary human T cells better cancer killers! biorxiv.org/content/10.110…

Interested in T cell biology? Cellular immunotherapies? Base editing? And an amazing example for scientific reproducibility- this @biorxivpreprint & tweetorial are for you! TL:DR- we made primary human T cells better cancer killers! biorxiv.org/content/10.110…

Scalable genetic screening for regulatory circuits using compressed Perturb-seq go.nature.com/46DCiQc

And I was absolutely thrilled to see that @BizarMd and lab @triciahoho @JCA_Melms @meri_rogava have also investigated the interplay between CMTM6 and CD58 sciencedirect.com/science/articl…

My first first-author pub is finally out in @Cancer_Cell! Endless thanks to @BizarMd @JCA_Melms and @meri_rogava for all their guidance scientifically and personally that made this happen. Tweetorial below from our pre-print for now! authors.elsevier.com/c/1hFn35TA51da…